YBYoram Bouhnik

Yoram Bouhnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoram Bouhnik has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn’s disease

    by Driffa Moussata, Gilles Boschetti, Carmen Stefanescu, Stephane Nancey, Yoram Bouhnik, Bernard Flourie

    Primary sclerosing cholangitis (PSC) is associated with ulcerative colitis and extensive colonic involvement or ileocolitis in Crohn's disease (CD). To our knowledge, no specific report of isolated ileitis associated with PSC in CD patients has been published in CD patients.


  • Open Access

    The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans

    by Yoram Bouhnik, Laurent Raskine, Guy Simoneau, Damien Paineau, Francis Bornet

    Background: Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS).Methods: Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart.Results (m ± SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 ± 0.59 to 9.39 ± 0.70; P = 0.02); 5 g/d (from 10.21 ± 0.21 to 10.67 ± 0.22; P = 0.03); 7.5 g/d (from 9.28 ± 0.49 to 9.85 ± 0.35;P = 0.01); 10 g/d (from 9.00 ± 0.81 to 10.18 ± 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2= 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested.Conclusion: This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers.


  • Open Access

    The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study

    by Yoram Bouhnik, Laurent Raskine, Guy Simoneau, Eric Vicaut, Christel Neut, Bernard Flourié, Fred Brouns, Francis R Bornet

    Background: Nondigestible carbohydrates (NDCHs) are fermented in the colon, where they can selectively promote the growth of bifidobacteria. Objective: Our aim was to determine the bifidogenic potential of different NDCHs used in human diets. Design: Two hundred healthy volunteers participated in this double-blind study. During phase 1 (screening), 64 volunteers were randomly assigned to 8 groups of 8 subjects each; for 7 d, they ingested 10 g/d of 1 of the 7 NDCHs tested or of the placebo. During phase 2 (dose-response study), 136 volunteers were randomly assigned to 4 groups of 32 subjects who received 2.5, 5.0, 7.5, or 10 g/d, respectively (8 subjects/dose), of one of the NDCHs that were proven to be bifidogenic during phase 1 and a fifth group of 8 subjects (control subjects) who received the placebo. Stools were recovered before and after NDCH consumption. Results: In phase 1, 4 NDCHs were found to be bifidogenic: short-chain fructooligosaccharides (P = 0.008), soybean oligosaccharides (P = 0.006), galactooligosaccharides (P < 0.0001), and type III resistant starch (P = 0.02); lactulose, long-chain inulin, and isomaltooligosaccharides were not bifidogenic. In phase 2, the effects of 7-d treatment on bifidobacteria concentrations were found to differ significantly among the 4 NDCHs (P = 0.009 for time × treatment interaction). However, no significant differences were found among doses, and there was no significant dose × time interaction. A low baseline bifidobacteria count was significantly associated with the bifidogenic response to treatment (P < 0.001). Conclusion: This study showed the different bifidogenic properties among the substrates and underlined the importance of taking into account the baseline bifidobacteria counts when evaluating the effect of the treatment.


  • Prospective, randomized, parallel‐group trial to evaluate the effects of lactulose and polyethylene glycol‐4000 on colonic flora in chronic idiopathic constipation

    by Y. Bouhnik, C. Neut, L. Raskine, C. Michel, M. Riottot, C. Andrieux, F. Guillemot, F. Dyard, B. Flourié

    Summary: Background : Although lactulose and polyethylene glycol are osmotic laxatives widely used in the treatment of chronic constipation, no study has been conducted to compare their actions on the colonic bacterial ecosystem, which has an important influence on host health.Aim : To assess the effects of lactulose and polyethylene glycol on the composition and metabolic indices of the faecal flora in patients with chronic idiopathic constipation.Methods : Sixty‐five patients with chronic idiopathic constipation were included in this controlled, multi‐centre, randomized, parallel‐group study. Participants received lactulose (Duphalac) or polyethylene glycol‐4000 (Forlax) powders for the first week at a fixed dosage at night (20 g/day); in the second week, patients were given the option to vary the dose according to efficacy and tolerance (10–30 g/day); for the last 2 weeks, treatment was administered at a fixed dosage based on the results of the second week (10–30 g/day). Stools were recovered for bacteriological analysis at days − 1, 21 and 28.Results : Clinical efficacy and tolerance were similar with both treatments. In the lactulose group, an increase in faecal bifidobacteria counts (P = 0.04) and β‐galactosidase activity (P < 0.001) was observed from day − 1 to day 28, whereas, in the polyethylene glycol group, there was a decrease in total short‐chain fatty acids (P = 0.02), butyrate (P = 0.04), acetate (P = 0.02) and faecal bacterial mass (P = 0.001). No differences were observed in stools with regard to the following parameters: counts of Lactobacillus, clostridial spores, Bacteroides and enterobacteria, pH, biliary acids and neutral sterol concentrations.Conclusions : Both lactulose and polyethylene glycol are efficacious and well tolerated. However, although lactulose can be considered as a pre‐biotic in constipated patients, polyethylene glycol produces signs of decreased colonic fermentation in the stool.


  • Lactulose ingestion increases faecal bifidobacterial counts: A randomised double-blind study in healthy humans

    by Y Bouhnik, A Attar, F A Joly, M Riottot, F Dyard, B Flourié

    Objective: Faecal bifidobacteria and lactobacilli, perceived as exerting health-promoting properties, may be increased by ingestion of high-dose lactulose in humans. The effects of low and well-tolerated doses of lactulose are not well known. The aim of the study was to assess the effects of prolonged low-dose lactulose administration on faecal bifidobacteria and selected metabolic indexes potentially involved in colonic carcinogenesis. Subjects and methods: In all, 16 healthy volunteers were included in this controlled, randomised, double-blind, parallel group trial. Participants ingested lactulose or placebo (sucrose) at a dose of 5 g b.i.d. for 6 weeks. Stools were regularly collected at baseline (d0), and after 3 (d21) and 6 (d42) weeks of sugar ingestion. Tolerance was evaluated using a daily chart. Results: Faecal bifidobacterial counts were higher in lactulose than in sucrose group (P=0.03). Lactulose ingestion led to a significant increase in faecal bifidobacteria counts from d0 to d21 and d42 ((ms.e.m.) 8.250.53, 8.960.40 and 9.540.28 log colony-forming units/g wet wt (CFU/g), respectively (P=0.048)). Placebo ingestion did not lead to any faecal bifidobacterial count change. Total anaerobes, Lactobacillus and pH were not significantly changed throughout the study in the two groups. Neither faecal bile acids nor neutral sterols were modified by lactulose. Excess flatus was more common in the lactulose group (P=0.03), but was very mild. Bloating and borborygmi did not differ between both the groups. Conclusions: A measure of 10 g lactulose/day increases faecal bifidobacterial counts, and lactulose fulfils the criteria requested to be considered as a prebiotic.


    • 15 November 2003
      • Vol. 53  (17) , 1953-61

    [Chronic diarrhea].

    by Yoram Bouhnik

  • Molecular inventory of faecal microbiota in patients with Crohn's disease

    by Irene Mangin, Regis Bonnet, Philippe Seksik, Malene Sutren, Lionel Rigottier-Gois, Yoram Bouhnik, Christel Neut, Jean-Frederic Colombel, Philippe Marteau, Joel Dore


    • 1 March 2003
      • Vol. 27, S98-103

    [Therapeutic strategies of fistulous Crohn's disease: medical or surgical treatment?].

    by Yoram Bouhnik, Yves Panis

  • Open Access

    Molecular Analysis of Intestinal Microbiota Composition to Evaluate the Effect of PEG and Lactulose Laxatives in Humans

    by Iréne Mangin, Yoram Bouhnik, Antonia Suau, Violaine Rochet, Laurent Raskine, Pascal Crenn, François Dyard, Jean-Claude Rambaud, Joël Doré

    Methods using bacteriological cultures allow only 30–50% of colonic bacterial populations to be detected. Our aim was to assess the effect of osmotic laxative administration on fecal bacteria during chronic idiopathic constipation, by a culture-independent molecular method. Forty-eight constipated patients were included in a randomized blinded trial and received either polyethylene glycol (PEG, n=23) or lactulose (n=25) for 28 days. Non-fermentable laxative (PEG) should not affect the bacterial groups, whereas fermentable (lactulose) could modulate them. The treatment dosage was 20 g per day for a 7-day period, then adjusted according to ef? cacy for 7 days and constant from 10 to 30 g per day for 14 days. Stools were collected at d0, d21 and d28, and analyzed by quantitative dot-blot hybridization using 16S ribosomal RNA-targeted oligonucleotide probes. We used a new Bifidobacterium group specific probe and five other probes to monitor the dominant groups of the intestinal bacteria: Bacteroides -Prevotella-Porphyromonas, Lactobacillus -Enterococcus- Streptococcus, enterobacteria: Clostridium coccoides and Clostridium leptum. Lactulose and PEG administration were associated with an increase of bifidobacterial rRNA index in 72% (18/25) and 17% (4/23) of cases, respectively. In the lactulose group, bifidobacterial rRNA index increased from [mean (SEM)] 1.1% (0.2%) at d0 (a), to 4.3% (1.2%) at d21 (b) and 4.5% (1.1%) at d28 (b), (a≠b, p=0.011). Lactulose treatment when administered at doses usually prescribed for constipation selectively stimulated bifidobacteria within the intestinal microbiota. The quantitative rRNA dot-blot hybridization method is an efficient tool to quantify intestinal bacteria, without the limitations of classical culture methods. Keywords: constipation, lactulose, quantitative dot-blot hybridization, Bifidobacterium probe, 16S rRNA.